|
Q1 FY2016
As of Mar 31, 2016
|
Q4 FY2015
As of Dec 31, 2015
|
Q3 FY2015
As of Sep 30, 2015
|
Q2 FY2015
As of Jun 30, 2015
|
Q1 FY2015
As of Mar 31, 2015
|
Q4 FY2014
As of Dec 31, 2014
|
Q3 FY2014
As of Sep 30, 2014
|
Q2 FY2014
As of Jun 30, 2014
|
Q1 FY2014
As of Mar 31, 2014
|
Q4 FY2013
As of Dec 31, 2013
|
Q3 FY2013
As of Sep 30, 2013
|
Q2 FY2013
As of Jun 30, 2013
|
Q1 FY2013
As of Mar 31, 2013
|
Q4 FY2012
As of Dec 31, 2012
|
Q3 FY2012
As of Sep 30, 2012
|
Q2 FY2012
As of Jun 30, 2012
|
Q1 FY2012
As of Mar 31, 2012
|
Q4 FY2011
As of Dec 31, 2011
|
Q3 FY2011
As of Sep 30, 2011
|
Q2 FY2011
As of Jun 30, 2011
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Prepaids, restricted investments and other current assets | ||||||||||||||||||||
| Prepaids and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Long-term investments | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Long-term inventories | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued compensation | ||||||||||||||||||||
| Accrued restructuring charges | ||||||||||||||||||||
| Accrued preclinical and clinical costs | ||||||||||||||||||||
| Other accrued liabilities | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Convertible senior notes, net | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Other noncurrent liability | ||||||||||||||||||||
| Stockholders' equity: | ||||||||||||||||||||
| Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued or outstanding | ||||||||||||||||||||
| Common stock, $0.001 par value; 200,000 shares authorized; 63,523 and 63,390 shares issued and outstanding, at March 31, 2016 and December 31, 2015, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...
